Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
CA 2428176 C · Owner: Presta, Marco · Inventors: Mantovani, Alberto; Bottazzi, Barbara; Presta, Marco
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 8, 2001 and granted February 5, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 8, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 8, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.